The impact of subthalamic deep brain stimulation on nigral neuroprotection - Myth or reality?

Neuromodulation

Volumn 13, Issue 3, 2010, Pages 160-167

  Harnack, Daniel ^a   Kupsch, Andreas ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

High frequency stimulation; microstimulator; movement disorders; neurostimulation; Parkinson's disease; rats; stimulator

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; PLACEBO; SELEGILINE;

BRADYKINESIA; BRAIN DEPTH STIMULATION; CELL DEATH; CLINICAL FEATURE; CLINICAL TRIAL; DYSKINESIA; DYSTONIA; HUMAN; MEDICAL ASSESSMENT; MEDICAL LITERATURE; NEUROMODULATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; REVIEW; SUBTHALAMIC NUCLEUS; TREMOR;

EID: 77954553468     PISSN: 10947159     EISSN: 15251403     Source Type: Journal    
DOI: 10.1111/j.1525-1403.2010.00282.x     Document Type: Review

References (62)

1. Kringelbach ML, Jenkinson N, Owen SL, Aziz TZ. Translational principles of deep brain stimulation. Nat Rev Neurosci 2007 8 : 623 635.
2. Volkmann J, Herzog J, Kopper F, Deuschl G. Introduction to the programming of deep brain stimulators. Mov Disord 2002 17 (Suppl. 3 S181 S187.
3. Gildenberg PL. Evolution of neuromodulation. Stereotact Funct Neurosurg 2005 83 : 71 79.
4. Heath RG. Psychiatry. Annu Rev Med 1954 5 : 223 236.
5. Mayberg HS, Lozano AM, Voon V et al. Deep brain stimulation for treatment-resistant depression. Neuron 2005 45 : 651 660.
6. Mallet L, Polosan M, Jaafari N et al. Subthalamic nucleus stimulation in severe obsessive-compulsive disorder. N Engl J Med 2008 359 : 2121 2134.
7. Delgado JM. Radiostimulation of the brain in primates and man. Fourth Becton, Dickinson and Company Oscar Schwidetzky Memorial Lecture. Anesth Analg 1969 48 : 529 542.
8. Benabid AL, Pollak P, Louveau A, Henry S, de Rougemont J. Combined (thalamotomy and stimulation) stereotactic surgery of the VIM thalamic nucleus for bilateral Parkinson disease. Appl Neurophysiol 1987 50 : 344 346.
9. Siegfried J, Shulman J. Deep brain stimulation. Pacing Clin Electrophysiol 1987 10 : 271 272.
10. Voges J, Hilker R, Botzel K et al. Thirty days complication rate following surgery performed for deep-brain-stimulation. Mov Disord 2007 22 : 1486 1489.
11. Hariz MI, Rehncrona S, Quinn NP, Speelman JD, Wensing C. Multicenter study on deep brain stimulation in Parkinson's disease: an independent assessment of reported adverse events at 4 years. Mov Disord 2008 23 : 416 421.
12. Deuschl G, Schade-Brittinger C, Krack P et al. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med 2006 355 : 896 908.
13. Weaver FM, Follett K, Stern M et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA 2009 301 : 63 73.
14. Kupsch A, Benecke R, Muller J et al. Pallidal deep-brain stimulation in primary generalized or segmental dystonia. N Engl J Med 2006 355 : 1978 1990.
15. Vidailhet M, Vercueil L, Houeto JL et al. Bilateral deep-brain stimulation of the globus pallidus in primary generalized dystonia. N Engl J Med 2005 352 : 459 467. (Pubitemid 40175972)
16. Vidailhet M, Vercueil L, Houeto JL et al. Bilateral, pallidal, deep-brain stimulation in primary generalised dystonia: a prospective 3 year follow-up study. Lancet Neurol 2007 6 : 223 229.
17. Houeto JL, Karachi C, Mallet L et al. Tourette's syndrome and deep brain stimulation. J Neurol Neurosurg Psychiatry 2005 76 : 992 995.
18. Krack P, Batir A, Van Blercom N et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 2003 349 : 1925 1934. (Pubitemid 37409709)
19. Rodriguez-Oroz MC, Obeso JA, Lang AE et al. Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up. Brain 2005 128 : 2240 2249.
20. Ostergaard K, Aa SN. Evolution of Parkinson's disease during 4 years of bilateral deep brain stimulation of the subthalamic nucleus. Mov Disord 2006 21 : 624 631.
21. Rodriguez MC, Obeso JA, Olanow CW. Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection. Ann Neurol 1998 44 : S175 S188.
22. DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Arch Neurol 1989 46 : 1052 1060.
23. Meissner W, Hill MP, Tison F, Gross CE, Bezard E. Neuroprotective strategies for Parkinson's disease: conceptual limits of animal models and clinical trials. Trends Pharmacol Sci 2004 25 : 249 253.
24. A randomized controlled trial comparing pramipexole with levodopa in early Parkinson's disease: design and methods of the CALM-PD Study. Clin Neuropharmacol 2000 23 : 34 44.
25. Whone AL, Watts RL, Stoessl AJ et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 2003 54 : 93 101.
26. Oertel WH, Wolters E, Sampaio C et al. Pergolide versus levodopa monotherapy in early Parkinson's disease patients: the PELMOPET study. Mov Disord 2006 21 : 343 353.
27. Fahn S. Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs later L-DOPA. Arch Neurol 1999 56 : 529 535.
28. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol 2002 59 : 1937 1943.
29. Olanow CW, Rascol O, Hauser R et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009 361 : 1268 1278.
30. Hilker R, Schweitzer K, Coburger S et al. Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. Arch Neurol 2005 62 : 378 382.
31. Bergman H, Wichmann T, Karmon B, DeLong MR. The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism. J Neurophysiol 1994 72 : 507 520.
32. Greenberg DA. Glutamate and Parkinson's disease. Ann Neurol 1994 35 : 639.
33. Piallat B, Benazzouz A, Benabid AL. Subthalamic nucleus lesion in rats prevents dopaminergic nigral neuron degeneration after striatal 6-OHDA injection: behavioural and immunohistochemical studies. Eur J Neurosci 1996 8 : 1408 1414.
34. Nakao N, Nakai E, Nakai K, Itakura T. Ablation of the subthalamic nucleus supports the survival of nigral dopaminergic neurons after nigrostriatal lesions induced by the mitochondrial toxin 3-nitropropionic acid. Ann Neurol 1999 45 : 640 651.
35. Chen L, Liu Z, Tian Z, Wang Y, Li S. Prevention of neurotoxin damage of 6-OHDA to dopaminergic nigral neuron by subthalamic nucleus lesions. Stereotact Funct Neurosurg 2000 75 : 66 75.
36. Carvalho GA, Nikkhah G. Subthalamic nucleus lesions are neuroprotective against terminal 6-OHDA-induced striatal lesions and restore postural balancing reactions. Exp Neurol 2001 171 : 405 417.
37. Paul G, Meissner W, Rein S et al. Ablation of the subthalamic nucleus protects dopaminergic phenotype but not cell survival in a rat model of Parkinson's disease. Exp Neurol 2004 185 : 272 280.
38. Blandini F, Nappi G, Greenamyre JT. Subthalamic infusion of an NMDA antagonist prevents basal ganglia metabolic changes and nigral degeneration in a rodent model of Parkinson's disease. Ann Neurol 2001 49 : 525 529.
39. Luo J, Kaplitt MG, Fitzsimons HL et al. Subthalamic GAD gene therapy in a Parkinson's disease rat model. Science 2002 298 : 425 429.
40. Bowenkamp KE, David D, Lapchak PL et al. 6-hydroxydopamine induces the loss of the dopaminergic phenotype in substantia nigra neurons of the rat. A possible mechanism for restoration of the nigrostriatal circuit mediated by glial cell line-derived neurotrophic factor. Exp Brain Res 1996 111 : 1 7.
41. Harvey DC, Lacan G, Tanious SP, Melega WP. Recovery from methamphetamine induced long-term nigrostriatal dopaminergic deficits without substantia nigra cell loss. Brain Res 2000 871 : 259 270.
42. Javoy-Agid F, Hirsch EC, Dumas S, Duyckaerts C, Mallet J, Agid Y. Decreased tyrosine hydroxylase messenger RNA in the surviving dopamine neurons of the substantia nigra in Parkinson's disease: an in situ hybridization study. Neuroscience 1990 38 : 245 253.
43. Kingsbury AE, Marsden CD, Foster OJ. The vulnerability of nigral neurons to Parkinson's disease is unrelated to their intrinsic capacity for dopamine synthesis: an in situ hybridization study. Mov Disord 1999 14 : 206 218.
44. Lopez-Flores G, Miguel-Morales J, Teijeiro-Amador J et al. Anatomic and neurophysiological methods for the targeting and lesioning of the subthalamic nucleus: cuban experience and review. Neurosurgery 2003 52 : 817 830.
45. Alvarez L, Macias R, Pavon N et al. Therapeutic efficacy of unilateral subthalamotomy in Parkinson's disease: results in 89 patients followed for up to 36 months. J Neurol Neurosurg Psychiatry 2009 80 : 979 985.
46. Tai CH, Boraud T, Bezard E, Bioulac B, Gross C, Benazzouz A. Electrophysiological and metabolic evidence that high-frequency stimulation of the subthalamic nucleus bridles neuronal activity in the subthalamic nucleus and the substantia nigra reticulata. FASEB J 2003 17 : 1820 1830.
47. Meissner W, Leblois A, Hansel D et al. Subthalamic high frequency stimulation resets subthalamic firing and reduces abnormal oscillations. Brain 2005 128 : 2372 2382.
48. Harnack D, Meissner W, Paulat R et al. Continuous high-frequency stimulation in freely moving rats: development of an implantable microstimulation system. J Neurosci Methods 2008 167 : 278 291.
49. Maesawa S, Kaneoke Y, Kajita Y et al. Long-term stimulation of the subthalamic nucleus in hemiparkinsonian rats: neuroprotection of dopaminergic neurons. J Neurosurg 2004 100 : 679 687.
50. Temel Y, Visser-Vandewalle V, Kaplan S et al. Protection of nigral cell death by bilateral subthalamic nucleus stimulation. Brain Res 2006 1120 : 100 105.
51. Wallace BA, Ashkan K, Heise CE et al. Survival of midbrain dopaminergic cells after lesion or deep brain stimulation of the subthalamic nucleus in MPTP-treated monkeys. Brain 2007 130 : 2129 2145.
52. Harnack D, Meissner W, Jira JA, Winter C, Morgenstern R, Kupsch A. Placebo-controlled chronic high-frequency stimulation of the subthalamic nucleus preserves dopaminergic nigral neurons in a rat model of progressive Parkinsonism. Exp Neurol 2008 210 : 257 260.
53. Harnack D, Winter C, Meissner W, Reum T, Kupsch A, Morgenstern R. The effects of electrode material, charge density and stimulation duration on the safety of high-frequency stimulation of the subthalamic nucleus in rats. J Neurosci Methods 2004 138 : 207 216.
54. Paul G, Reum T, Meissner W et al. High frequency stimulation of the subthalamic nucleus influences striatal dopaminergic metabolism in the naive rat. Neuroreport 2000 11 : 441 444.
55. Bruet N, Windels F, Bertrand A, Feuerstein C, Poupard A, Savasta M. High frequency stimulation of the subthalamic nucleus increases the extracellular contents of striatal dopamine in normal and partially dopaminergic denervated rats. J Neuropathol Exp Neurol 2001 60 : 15 24.
56. Meissner W, Harnack D, Reese R et al. High-frequency stimulation of the subthalamic nucleus enhances striatal dopamine release and metabolism in rats. J Neurochem 2003 85 : 601 609.
57. Lee KH, Blaha CD, Harris BT et al. Dopamine efflux in the rat striatum evoked by electrical stimulation of the subthalamic nucleus: potential mechanism of action in Parkinson's disease. Eur J Neurosci 2006 23 : 1005 1014.
58. Meissner W, Harnack D, Paul G et al. Deep brain stimulation of subthalamic neurons increases striatal dopamine metabolism and induces contralateral circling in freely moving 6-hydroxydopamine-lesioned rats. Neurosci Lett 2002 328 : 105 108.
59. Meissner W, Reum T, Paul G et al. Striatal dopaminergic metabolism is increased by deep brain stimulation of the subthalamic nucleus in 6-hydroxydopamine lesioned rats. Neurosci Lett 2001 303 : 165 168.
60. Breit S, Schulz JB, Benabid AL. Deep brain stimulation. Cell Tissue Res 2004 318 : 275 288. Epub 2004 Aug 19. Review.
61. Shaw VE, Keay KA, Ashkan K, Benabid AL, Mitrofanis J. Dopaminergic cells in the periaqueductal gray matter of MPTP-treated monkeys and mice; patterns of survival and effect of deep brain stimulation and lesion of the subthalamic nucleus. Parkinsonism Relat Disord. 2010. 16 : 338 344.
62. Spieles-Engemann AL, Behbehani MM, Collier TJ et al. Stimulation of the rat subthalamic nucleus is neuroprotective following significant nigral dopamine neuron loss. Neurobiol Dis 2010. 39 : 105 115.